COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND
DOI:
https://doi.org/10.17501/24246735.2024.9105Keywords:
non-small cell lung cancer, osimertinib, cost-effectiveness, epidermal growth, factor receptor, adjuvant therapyAbstract
Lung cancer is the most common cancer and the leading cause of cancer death worldwide. One-third of non-small cell lung cancer (NSCLC) patients are diagnosed in resectable stage, for which curative surgery is the cornerstone of treatment. Adjuvant osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), was shown to significantly reduce recurrence and prolong survival for completely resected EGFR-mutated NSCLC. We performed a cost-effectiveness analysis of adjuvant osimertinib compared to placebo in patients with resected stage IB to IIIA EGFR-mutated NSCLC using Thailand’s societal perspective. A Markov model estimated the lifetime costs and health benefits of osimertinib versus placebo, including three health states: disease-free, recurrent disease, and death, tracked over a lifetime using 4-week cycles. Results were reported as 2023 USD incremental cost-effectiveness ratios (ICERs) per quality-adjusted life year (QALY) gained. The result showed that a virtual patient receiving osimertinib had 2.36 more QALYs than one receiving the placebo, at an incremental cost of 62,604.90 USD. Compared to the placebo group, treatment with adjuvant osimertinib had an ICER of 26,474.02 USD/QALY gained. Therefore, osimertinib was not cost-effective at the Thai willingness-to-pay (WTP) threshold of 4,619 USD/QALY gained. The drug price would need to be reduced by at least 85.07% for osimertinib to be cost-effective. In summary, adjuvant osimertinib for resected EGFR-mutated NSCLC patients is not cost-effective according to Thailand’s current WTP threshold. Negotiating drug costs and managed entry agreements could improve patient access to this effective treatment.
Downloads
References
BANK OF THAILAND. (2023). Foreign Exchange Rate. https://www.bot.or.th/en/home.html
Drug And Medical Supply Information Center, M. o. P. H. (2023). Reference cost of medicine. https://dmsic.moph.go.th/index./drugsearch/1
Grutters, J. P., Joore, M. A., Wiegman, E. M., Langendijk, J. A., de Ruysscher, D., Hochstenbag, M., Botterweck, A., Lambin, P., & Pijls-Johannesma, M. (2010). Health-related quality of life in patients surviving non-small cell lung cancer. Thorax, 65(10), 903-907. https://doi.org/10.1136/thx.2010.136390
Guideline Development Working Group. (2019). Guideline for Health Technology Assessment in Thailand Updated Edition.
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., & Reck, M. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 339-357. https://doi.org/10.1016/j.annonc.2022.12.009
Herbst, R. S., Wu, Y.-L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., Laktionov, K., Kim, S.-W., Yu, C.-J., Vu, H. V., Lu, S., Lee, K. Y., Mukhametshina, G., Akewanlop, C., Marinis, F. d., Bonanno, L., Domine, M., . . . Tsuboi, M. (2023). Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology, 41(10), 1830-1840. https://doi.org/10.1200/jco.22.02186
Kangwanrattanakul, K. (2022). A systematic review of health state utility values in Thai cancer patients. Expert Review of Pharmacoeconomics & Outcomes Research, 22(8), 1171-1186. https://doi.org/10.1080/14737167.2022.2123796
Lemmon, C. A., Zabor, E. C., & Pennell, N. A. (2022). Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. The Oncologist, 27(5), 407-413. https://doi.org/10.1093/oncolo/oyac021
Limwattananon, C., Limwattananon, S., Waleekhachonloet, O., & Rattanachotphanit, T. (2018). Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. Lung Cancer, 120, 91-97.
Lu, S., Kato, T., Dong, X., Ahn, M.-J., Quang, L.-V., Soparattanapaisarn, N., Inoue, T., Wang, C.-L., Huang, M., Yang, J. C.-H., Cobo, M., Özgüroğlu, M., Casarini, I., Khiem, D.-V., Sriuranpong, V., Cronemberger, E., Takahashi, T., Runglodvatana, Y., Chen, M., . . . Ramalingam, S. S. (2024). Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine. https://doi.org/doi:10.1056/NEJMoa2402614
Ministry of Public Health. (2022). Public Health Statistics A.D.2022. https://spd.moph.go.th/wp-content/uploads/2023/11/Hstatistic65.pdf
National Cancer Institute. (2021). Hospital-based cancer registry. https://www.nci.go.th/th/cancer_record/download/HOSPITAL-BASED_2021.pdf
National Comprehensive Cancer Network. (2024). Non-Small Cell Lung Cancer (Version1.2024). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Papadimitrakopoulou, V. A., Mok, T. S., Han, J. Y., Ahn, M. J., Delmonte, A., Ramalingam, S. S., Kim, S. W., Shepherd, F. A., Laskin, J., He, Y., Akamatsu, H., Theelen, W. S. M. E., Su, W. C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., & Wu, Y. L. (2020). Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of Oncology, 31(11), 1536-1544. https://doi.org/10.1016/j.annonc.2020.08.2100
Permsuwan, U., Niamhun, N., Tanatip, N., & Thongprasert, S. (2014). Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis. Value in Health Regional Issues, 3, 39-43. https://doi.org/https://doi.org/10.1016/j.vhri.2013.12.001
Ramalingam, S. S., Kato, T., Dong, X., Ahn, M.-J., Quang, L.-V., Soparattanapaisarn, N., Inoue, T., Wang, C.-L., Huang, M., & Yang, J. C.-H. (2024). Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. In: American Society of Clinical Oncology.
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M.-C., Imamura, F., Kurata, T., . . . Soria, J.-C. (2019). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382(1), 41-50. https://doi.org/10.1056/NEJMoa1913662
Reechaipichitkul, W., Thavornpitak, Y., & Sutra, S. (2014). Burden of adult pneumonia in Thailand: a nationwide hospital admission data 2010. J Med Assoc Thai, 97(3), 283-292.
Reungwetwattana, T., Oranratnachai, S., Puataweepong, P., Tangsujaritvijit, V., & Cherntanomwong, P. (2020). Lung cancer in Thailand. Journal of Thoracic Oncology, 15(11), 1714-1721.
Riewpaiboon, A. (2009). Standard cost list for health technology assessment. http://www.hitap.net/costingmenu/
Riewpaiboon, A., Sirisuksan, V., Rungmaitree, S., & Chokephaibulkit, K. (2020). Economic burden of pneumonia, sepsis and meningitis among children aged up to 5 years old at a tertiary care hospital in Thailand: an input for economic evaluation of vaccination. Pharmaceutical Sciences Asia, 47(4).
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y., & Berille, J. (2000). Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. Journal of Clinical Oncology, 18(10), 2095-2103. https://doi.org/10.1200/jco.2000.18.10.2095
Siriraj hospital. (2023). Laboratory examination manual, Department of Clinical Pathology Faculty of Medicine Siriraj Hospital. https://www.si.mahidol.ac.th/th/manual/Project/service.html
Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., Rimner, A., Wu, Y.-L., Özgüroğlu, M., Lee, K. H., Kato, T., Wit, M. d., Kurata, T., Reck, M., Cho, B. C., . . . Antonia, S. J. (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 40(12), 1301-1311. https://doi.org/10.1200/jco.21.01308
Sukauichai, S., Maneenil, K., Supavavej, A., Paul, V., Benjawongsathien, D., Chantharakhit, C., Neesanun, S., Chayangsu, C., Bowornkitiwong, T., & Sukaraphat, N. (2022). EGFR mutation-positive lung cancer in real-world treatment outcomes: A multicenter study from Thailand. Asian Pacific Journal of Cancer Care, 7(4), 643-650.
Thaweethamcharoen, T., Sakulbumrungsil, R., Nopmaneejumruslers, C., & Vasuvattakul, S. (2014). Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis. Value Health Reg Issues, 3, 44-49. https://doi.org/10.1016/j.vhri.2014.01.001
The National Cancer Institute Library. (2015). Clinical practice guideline for lung cancer Thailand. https://drive.google.com/file/d/1Z7KGYOdQXYeQBf_lYpxDwgE7_sUOZokj/view
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., de Marinis, F., Shepherd, F. A., Lee, K. H., Le, N. T., Dechaphunkul, A., Kowalski, D., Poole, L., Bolanos, A., Rukazenkov, Y., & Wu, Y.-L. (2023). Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. New England Journal of Medicine, 389(2), 137-147. https://doi.org/10.1056/NEJMoa2304594
Verhoek, A., Cheema, P., Melosky, B., Samson, B., Shepherd, F. A., de Marinis, F., John, T., Wu, Y.-L., Heeg, B., & Van Dalfsen, N. (2023). Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. PharmacoEconomics-Open, 7(3), 455-467.
Vila Pérez, A., Alegre-del Rey, E. J., Fénix-Caballero, S., Špacírová, Z., Rosado Varela, P., & Olry de Labry Lima, A. (2023). Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR. Supportive Care in Cancer, 32(1), 67. https://doi.org/10.1007/s00520-023-08239-8
World Health Organization. (2022). Incidence cancer. https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&group_populations=0&multiple_populations=1&populations=764
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., Vu, H.-V., Lu, S., Lee, K.-Y., Akewanlop, C., Yu, C.-J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., . . . Herbst, R. S. (2020). Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer. New England Journal of Medicine, 383(18), 1711-1723. https://doi.org/10.1056/NEJMoa2027071
Zhou, X., Du, J., Xu, G., Chen, C., Zheng, B., & Chen, J. (2022). Cost‐effectiveness of osimertinib versus placebo in resected EGFR‐mutated non‐small cell lung cancer in China. Cancer Medicine, 11(23), 4449-4456.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Supitchaya Changsatja, Chayanis Kositamongkol, Lucksamon Thamlikitkul, Pochamana Phisalprapa, Touchanun Komonpaisarn
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Conference Proceedings of International Conference on Public Health is entirely Open Access, which means that all published content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this Proceedings journal without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
Authors who publish with Conference Proceedings agree to the following terms:
- Authors retain copyright and grant the Proceedings of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this conference proceedings.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the proceeding's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this conference proceedings.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Licensing
Published articles are licensed under a Creative Commons Attribution 4.0 International License.
